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A consensus view of soyabean phyto-oestrogens in clinical interventions in post-menopausal
women is presented that is based on data from the EU-funded project Phytohealth. The phyto-
oestrogens, primarily genistein and daidzein, were given as soyabean-protein isolates, whole-
soyabean foods or extracts, supplements or pure compounds. A comprehensive literature search
was conducted with well-defined inclusion or exclusion criteria. For areas for which substantial
research exists only placebo-controlled double-blind randomised controlled trials (RCT)
conducted on healthy post-menopausal women were included. For emerging areas all available
human studies in post-menopausal women were reviewed. In order to make cross comparisons
between studies the doses of isoflavones were calculated as aglycone equivalents. There is a
suggestion, but no conclusive evidence, that isoflavones from the sources studied so far have a
beneficial effect on bone health. The consumption of whole-soyabean foods and soyabean-
protein isolates has some beneficial effects on lipid markers of cardiovascular risk. The con-
sumption of isolated isoflavones does not affect blood lipid levels or blood pressure, although it
may improve endothelial function. For menopausal symptoms there is currently limited
evidence that soyabean-protein isolates, soyabean foods or red-clover (Trifolium pratense L.)
extract are effective but soyabean isoflavone extracts may be effective in reducing hot flushes.
There are too few RCT studies to reach conclusions on the effects of isoflavones on breast
cancer, colon cancer, diabetes or cognitive function. The health benefits of soyabean phyto-
oestrogens in healthy post-menopausal women are subtle and even some well-designed studies
do not show protective effects. Future studies should focus on high-risk post-menopausal
women, especially in the areas of diabetes, CVD, breast cancer and bone health.
Genistein: Daidzein: Bioavailability: Bone health: CVD
The current interest in soyabean and its phyto-oestrogen
component in relation to human health has resulted in a
substantial number of publications on the potential clinical
efficacy of these compounds to improve health in meno-
pausal women. However, although numerous reviews have
been presented, to date a consensus on the potential
importance of these compounds for menopausal health
following a critical grading of the studies and their results
has not been conducted. The focus of the current review is
specifically to grade the evidence from clinical studies
addressing the effects of intervention of soyabean iso-
flavones (for chemical structures of the aglycones, see
Abbreviations: RCT, randomised controlled trial; SPI, soyabean-protein isolate.
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Fig. 1) fed as soyabean-protein isolates (SPI), whole-
soyabean foods or extracts, supplements or pure com-
pounds and reach a consensus on optimal dose, food source
and duration of use for each of the health outcomes. This
procedure will be conducted in depth for bone health, CVD
and menopausal symptoms and current knowledge
summarised for other areas of growing interest, including
cancer, cognition and diabetes. The comparability of
clinical studies is confounded by the variability in phyto-
oestrogen composition and dose administered in the inter-
vention studies. Thus, before reviewing the health effects
the available evidence on factors influencing the bio-
availability of isoflavones will be reviewed, since the
intervention studies have used different doses and sources
of isoflavones to examine the various health effects.
The consensus view presented is based on data from the
EU-funded project Phytohealth, a pan-European network
of excellence funded by the EU (QLKII-CT-2002-02453),
which has brought together a multidisciplinary team of
scientists, including toxicologists, clinicians and nutri-
tionists to evaluate the current research in the phyto-
oestrogens field and identify current gaps in knowledge.
Materials and methods
A literature search was conducted (up to June 2005)
using MEDLINE (PubMed), EMBASE and the Cochrane
Collaboration (The Cochrane Library). The search includ-
ed the following keywords: phytoestrogens, isoflavones,
genistein, daidzein, equol, soy (a); cross-referenced with
the key words: post-menopausal, hot flushes, osteoporosis,
bone mineral density, bone metabolism, cardiovascular,
endothelial function, vascular reactivity, blood pressure,
lipid profile, breast, colon, cognition.
In order to make cross comparisons between studies that
used a range of sources of isoflavones the doses of iso-
flavones were calculated as aglycone equivalents. A panel
of Phytohealth members reviewed the studies and classi-
fied them according to the grading criteria proposed by
Harbour & Miller (2001; Table 1).
For areas in which substantial research has been con-
ducted only studies with a high grade (‡1+) have been
considered in the formulation of the consensus statement.
Only placebo-controlled double-blind randomised con-
trolled trials (RCT) conducted on healthy women >1 year
post-menopausal (for hot flushes >6 months and
biochemically defined) were included. Evaluation of
methodological strength was conducted following the
methodology outlined by Jadad et al. (1996). In particular,
absence of bias, quality of data collection, quality of
reporting of study methodology, adequate power calcula-
tions, clear characterisation of dose and composition of
phyto-oestrogen product were considered. Additional
inclusion criteria were applied for each specific health
outcome. For bone health only studies with a duration ‡ 6
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Fig. 1. A comparison of the chemical structures of isoflavone metabolites and the gut metabolite equol.
Table 1. Grading criteria applied to the studies assessed in the present review
1++ High-quality meta-analysis, systematic reviews of RCT or RCT with a very low risk of bias
1+ Well-conducted meta-analysis, systematic reviews of RCT or RCT with a low risk of bias
1- Meta-analysis, systematic reviews of RCT or RCT with a high risk of bias
2++ High-quality systematic reviews of case–control or cohort studies or high-quality case–control or cohort studies with a very low risk of
confounding, bias or chance and a high probability that the relationship is causal
2+ Well conducted case–control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that the
relationship is causal
2- Case–control or cohort studies with a high risk of confounding, bias or chance and significant risk that the relationship is not causal
3 Non-analytical studies, e.g. case reports, case series
4 Expert opinion
RCT, randomised controlled trials.
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months were included, and for cardiovascular health and
menopausal symptoms only studies with a duration ‡4
weeks were included. For menopausal symptoms only
studies purposefully designed for this outcome were
included.
For emerging areas, including cognitive function, breast
and colo-rectal health and diabetes, all available human
studies in post-menopausal women (or mixed menopausal
status studies) were considered and reviewed (level of
evidence of 2+ and above). All papers reviewed by the
panel were tabulated, with the studies that matched the
criteria for inclusion in the consensus paper presented
within the text. The panel then weighted the evidence and
a statement was formulated for each health effect and
assigned a grade, based on the quality of the studies used.
Grading was assigned according to the methodology out-
lined in Table 2 (Agency for Health Care Policy and
Research, 1992).
Results and discussion
Bioavailability and sources
The importance of understanding factors influencing
absorption and metabolism as these factors may influence
potential clinical effects under study. During the course
of studies on health effects the isoflavone test compounds
are consumed in various forms, together with other foods,
in various doses and by different age-groups. All these
variables could influence the bioavailability and therefore
the final outcome of the study. This section examines how
the outcome of human intervention studies could be
affected, either positively or negatively, by bioavailability
factors. Examination of the data (Tables 4–10) reveals that
a range of sources of isoflavones has been used: pure
compound (tablets or capsules), extracts of soyabean germ
or red clover (Trifolium pratense L.), soyabean flour, soya
beverages, isoflavone-enriched soyabean protein, soya-
bean-protein drinks or SPI. Many of the studies were long
term and during each study the overall diet was not fully
monitored, implying that the effect of foods on bio-
availability also needs to be considered.
Variables in isoflavone bioavailability: food matrix and
storage. One of the most important factors is to measure
the amount of isoflavone in the food or supplement at the
moment of consumption, since storage and processing
influence the amount of isoflavone in the final product
and the stability of the various isoflavones is different
depending on the structure (Mahungu et al. 1999; Xu et al.
2002; Eisen et al. 2003; Lee et al. 2003). Other factors in
the diet, such as fibre, can also affect the bioavailability
(Tew et al. 1996). The source of the isoflavones and hence
the food matrix in which the compound is delivered seems
to be less important, and generally studies have found no
difference in the bioavailability between cooked soya-
beans, textured vegetable protein, tofu or tempeh (Xu et al.
2000) or soya-milk powder or soyabean germ (Zheng et al.
1999).
Variables in isoflavone bioavailability: chemical nature
of the isoflavone. The chemical form of the isoflavone
may affect the bioavailability, and there is some evidence
to suggest that bioavailability is different following con-
sumption of fermented soyabean products (containing
mainly aglycones) compared with ingestion of non-
fermented soyabean products (containing the naturally-
occurring isoflavone glucosides (Izumi et al. 2000; Setchell
et al. 2001)). This aspect of aglycone v. glycoside is an
important factor in designing an intervention study. The
pharmaco-kinetic values from sixteen studies are shown in
Table 3. There is a linear increase in peak mean plasma
concentration for daidzein between 1 and 31mmol/kg body
weight (R2 0.958) and for genistein between 0.2 and
59mmol/kg body weight (R2 0.974). There is also a corre-
lation, although weaker, for the glucosides (R2 0.716 and
R2 0.730 respectively). The area under the curve, urinary
excretion and faecal excretion show no significant corre-
lations with dose for any of the compounds between the
selected studies.
Variables in isoflavone bioavailability: effect of age.
No difference has been found in the pharmaco-kinetics of
either genistein or daidzein between pre- and post-
menopausal women (Setchell et al. 1997, 2003a; Lu &
Anderson, 1998; Faughnan et al. 2004).
Variables in isoflavone bioavailability: frequency of
ingestion. No significant differences have been observed
in the pharmaco-kinetics of [13C]daidzein or [13C]genistein
after 2 weeks wash-out or after 7 d of soyabean consump-
tion (Setchell et al. 2003b). After 1 month of daily soya-
milk feeding there is a decrease in the urinary excretion of
genistein and daidzein, whereas that of equol increases;
however, this effect is only detected in women and not in
men (Lu & Anderson, 1998).
Metabolism as a confounder or additional variable in
efficacy studies: equol production. The ability to convert
daidzein to equol is observed in about 30–50% of individ-
uals. An analysis by Setchell et al. (2002a) has shown that
Table 2. Grading methodology applied to the studies (from Agency for Health Care Policy and Research, 1992)
A At least one meta-analysis systematic review or at least one RCT 1++ performed on the target population; alternatively, a systematic
review of RCT or collection of evidences from studies of 1+ offering consistent evidence and with outcomes directly applicable to
the target population
B Evidence that can be classified of level 2++ , which is consistent and with outcomes directly applicable to the target population;
alternatively, evidence that can be extrapolated from studies 1++ or 1+ not directly applicable to the target population
C Evidence that can be classified of level 2+ , 2++ , which is consistent and with outcomes directly applicable to the target population;
alternatively, evidence that can be extrapolated from studies 2++ not directly applicable to the target population
D Evidence of level 3 or 4, or evidence extrapolated from studies of level £2+
GPP Good practice point; on the basis of expert opinion, not supported by experimental evidence
1++ , 1+ , 2++ , 2+ , 3, 4, levels of grading applied to the studies (for details of criteria, see Table 1); RCT, randomised controlled trials.
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the ability to produce equol is associated with an increased
benefit of isoflavones on bone mineral density. Equol pro-
duction is influenced by intestinal microflora composition,
gut transit time and the redox potential of the colon
(Setchell et al. 1984). During the first months of life
the plasma and urine levels of equol are lower than those
in adults, probably because of an immature gut flora
(Setchell et al. 1997). Ingestion of daidzin results in a
higher equol production than after ingestion of the agly-
cone daidzein alone (Setchell et al. 1997; Lampe et al.
1998; Zubik & Meydani, 2003), and equol production is
more prevalent in subjects with a high consumption of
carbohydrates and dietary fibre and a low dietary fat:fibre
(Lampe et al. 1998; Watanabe et al. 1998; Rowland et al.
1999).
Metabolism as a confounder or additional variable in
efficacy studies: chemical forms in the plasma. In most
subjects the plasma curves for isoflavones show a double
peak consisting of a sharp early peak followed by a later
larger and more rounded peak, representing a combination
of entero-hepatic recycling, together with absorption in the
duodenum–jejunum followed by (higher) absorption in the
colon (King & Bursill, 1998; Setchell, 1998; Day et al.
2000). Isoflavones are deconjugated during absorption
(Day et al. 2000; Setchell et al. 2002b; Wilkinson et al.
2003) and are found in plasma as conjugates of sulfate and
glucuronic acid. Genistein glucuronide exhibits a later time
to reach maximum plasma concentration than genistein
sulfate, daidzein sulfate and daidzein glucuronide, and both
genistein conjugates show a longer half-life than the
corresponding daidzein conjugates (Shelnutt et al. 2002).
The frequency of isoflavone consumption has no effect on
the proportion of glucuronides, sulfates and aglycones of
genistein and daidzein in plasma or urine (Zhang et al.
2003). The relative biological activities of the isoflavone
conjugates in the plasma are dependent on the chemical
structure (Turner et al. 2004).
Bioavailability in human intervention studies. It can be
concluded that understanding the bioavailability of the
isoflavones in a given foodstuff is essential before
embarking on a study of the clinical effects. Most impor-
tantly, it is essential to measure accurately the amount and
form of isoflavones at the point of consumption during the
study, and to check this information at regular intervals.
Taken together, factors such as glycoside v. aglycone, food
source, the ‘equol producer’ state of the volunteers and
the influence of other foods eaten during the study can
determine whether a significant biological or clinical effect
is observed, or not.
Health effects: bone
Consensus statement for effects on bone: grade A
recommendation. As a result of limited relevant studies
and differences in methodological approaches there is a
suggestion, but no conclusive evidence, that isoflavones
from the sources studied so far have a beneficial effect on
bone health. A recommendation cannot therefore be made
at the current time and there is a need for further high-
quality long-term (>1 year) studies to clarify the effect of
phyto-oestrogens on bone.
Summary of data for bone health. Bone health is a
major concern as women age, and femur or vertebral
fractures may severely affect the quality of life. Hormone-
replacement therapies have been the first line of treatment
of hormone-related osteoporosis, but major side effects
preclude their universal use. The observation that South-
East Asian women report a lower occurrence of osteo-
porosis has led to the hypothesis that soyabean or soyabean
phyto-oestrogens are a possible alternative option for
the prevention of osteoporosis. Thirty-one studies have
examined the effects of phyto-oestrogens on bone mass
or bone turnover, or both, but only six studies met the
inclusion criteria (Potter et al. 1998; Clifton-Bligh et al.
2001; Morabito et al. 2002; Chen et al. 2003; Gallagher
et al. 2004; Kreijkamp-Kaspers et al. 2004; Table 4).
Three of these studies used pure compounds or extracts
and three studies provided foods containing soyabean
protein or SPI.
Of the three studies that used soyabean isoflavone
extracts or pure genistein, two are suggestive of an effect
on bone mineral density at doses ranging from 35 to 54mg
aglycone equivalents. Only one of the three studies per-
formed with SPI shows an effect on bone mineral density
at a dose of 56mg aglycone equivalents, while the two
other studies show no effect with doses ranging from 4 to
103mg aglycone equivalents. The age since menopause
does not appear to influence the effect of phyto-oestrogens
on bone mineral density or bone mineral content in all
studies.
Only three of the identified studies included biomarkers
of bone formation or bone resorption. One study, which
used SPI (Gallagher et al. 2004), shows no effect on bone
markers, and the study that used genistein (54mg) shows
Table 3. Pharmaco-kinetic data for daidzein, genistein and their glucosides from sixteen published studies
(Values are presented as the average of all studies and the range)
cmax* (mM)
tmax (h) t1/2 (h)
AUC* (mM/h)
Urinary excretion (%) Faecal excretion (%)
Av Range Av Range Av Range Av Range
Daidzein 0.54 6.2 4.0–8.3 7.7 4.2–16 18† 34† 26–50
Genistein 0.49 5.7 3.5–9.3 9.5 6.1–17 11† 11† 8.3–18
Daidzin 0.77 7.5 5.5–9.2 7.0 4.6–9.5 6 50† 15–56 3.7† 0.6–5.5
Genistin 0.97 6.7 4.0–9.3 9.5 5.7–18 16† 19† 5.3–39 3.0† 0.5–8.6
Av, average; cmax, peak mean plasma concentration; tmax, time to reach maximum plasma concentration; t1/2, half-life; AUC, area under curve.
*Average values after ingestion of 1mmol/kg body weight.
†High uncertainty on value as a result of large variance between studies.
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an increase in bone formation biomarkers and a reduction
in bone resorption biomarkers.
Health effects: cardiovascular effects
Consensus statement for cardiovascular effects: grade
A recommendation. On the basis of the available
evidence, the panel has concluded that the consumption of
whole-soyabean foods and SPI has some beneficial effects
on lipid markers of cardiovascular risk in healthy post-
menopausal women. The consumption of isolated iso-
flavones does not affect blood lipid levels or blood
pressure, although it may improve endothelial function.
Adequately-powered human intervention studies that can
definitively establish the benefits of either encapsulated
isoflavones or isoflavone-fortified foods are needed, partic-
ularly in women at high risk.
Summary of data for cardiovascular effects. Epidemio-
logical evidence from human subjects suggests that high
soyabean consumption, the main dietary source of iso-
flavones, is cardioprotective. To date the predominant
interest has been in relation to the hypercholesterolaemic
effects, stimulated by the significant lipoprotein effects
observed in the meta-analysis of Anderson et al. (1995).
More recently, two further meta-analyses have investigated
the effects of soyabean foods, soyabean protein and
soyabean-isoflavone extracts on serum lipids (Weggemans
& Trautwein, 2003; Yeung & Yu, 2003). In a meta-analysis
of seventeen randomised trials (Yeung & Yu, 2003) it has
been found that isoflavone extracts (encapsulated) have no
effects on serum lipids. Furthermore, since the studies of
soyabean foods and SPI were heterogeneous in design and
not statistically well-powered it is, therefore, not possible
to draw conclusions on the lipid-lowering benefits of iso-
flavones contained in soyabean. Weggemans & Trautwein
(2003) have analysed the independent effects of soyabean-
associated isoflavones on plasma LDL- and HDL-
cholesterol in ten randomised controlled studies and have
concluded that differences in isoflavone content of soya-
bean protein are not associated with concentrations of
these lipoproteins. Thus, currently, there is uncertainty
about extent of the contribution of soyabean isoflavones to
the cholesterol-lowering effects that are reported in con-
trolled trials of soyabean and soyabean products. However,
data from in vitro and animal experiments are emerging
that suggests that isoflavones may be cardioprotective by
mechanisms independent of blood lipids (see review, Hall
et al. 2004), but these underlying mechanisms are only
partly understood. As a result, more recently, attention has
focused on the potential effects of phyto-oestrogens on
blood pressure, in vivo measures of vascular function such
as flow-mediated dilation and novel biomarkers of CVD
risk, and to date these studies have not been systematically
reviewed.
Of the sixty-three studies conducted to date forty studies
have used soyabean foods or soyabean-protein extracts or
Table 4. Effects of soyabean isoflavones on bone biomarkers and bone density
Reference
Age
(years)*
Subjects
completed
Study
design
Duration
(months)
Isoflavone
source
Daily dose
(mg aglycone
equivalents)
Bone
biomarkers
Bone
density
Soyabean protein
Gallagher et al.
(2004)
40–62
55 (SD 1)
50 Pa 9 SPI 2, 32, 60 BF (BGP, BALP) no
effect BR (NTx)
no effect
No effect
Potter et al. (1998) 49–83 66 Pa 6 SPI 35, 56 NA 56 mg: › 2.2% for
BMD for lumbar
spine;
35 mg: no effect
Kreijkamp-Kaspers
et al. (2004)
60–75 175 Pa 12 SPI 99 NA No effect
Isoflavone extracts
Chen et al. (2003) 48–62 175 Pa 12 Soyabean
-germ
extract
25, 50 NA 50 mg: no effect on
BMD; › 0.5% for
BMC for total hip
and trochanter;
25 mg: no effect
Clifton-Bligh et al.
(2001)
57 (SD 5) 46 Pa 6 RC extract 17, 35, 53 BR (fDPD): no
effect
53 mg: › 3% for
BMD for proximal
radius and ulna
35 mg: › 4.1% for
BMD for proximal
radius and ulna
17 mg: no effect
Morabito et al.
(2002)
47–57 90 Pa 12 Genistein 54 ›BF (BGP, BALP) ﬂ
BR (fPyd, fDpd)
›3% for BMD for
hip and spine
Pa, parallel; BF, bone formation; BGP, bone Gla protein (osteocalcin); BALP, bone alkaline phosphatase; BR, bone resorption; NTx, urinary N telopeptide; NA, not
available; BMD, bone mineral density; BMC, bone mineral content; fPyd, free pyridinoline; fDPD, free deoxypyridinoline; SPI, soyabean-protein isolate; RC, red
clover (Trifolium pratense L); ›, increase; ﬂ, decrease.
*Values shown are ranges and/or means and standard deviations.
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SPI and twenty-three have used isoflavone extracts from
soyabean or other sources (e.g. red clover). Following
grading of evidence three soyabean food studies, thirteen
SPI studies and fifteen isoflavone-extract studies were
included for further review. These data suggest that soya-
bean food and soyabean protein interventions may have a
beneficial effect on lipoprotein status (Table 5), while there
is limited data to support a lipid-lowering effect of iso-
flavone extracts. The data on the effects of soyabean foods
and soyabean protein on blood pressure are equivocal, but
it is clear that there is no evidence for an effect of iso-
flavone extracts on blood pressure.
Although there is growing interest in the potential direct
effects of isoflavones on the arterial wall, only limited
studies matching the present criteria have been conducted
to date and the available data are inconclusive (Table 6).
Increased flow-mediated dilation (Cuevas et al. 2003),
decreased brachial artery peak flow velocity (Steinberg
et al. 2003) and improved peripheral vascular resistance
(Teede et al. 2001) have been demonstrated following
soyabean protein, although not all studies are in agreement
in their findings (Blum et al. 2003b). Some isoflavone
extract studies have found positive effects on in vivo
endothelial function measurements (Nestel et al. 1997,
1999; Squadrito et al. 2002, 2003; Teede et al. 2003).
Other studies, however, have found no effect of isoflavones
on in vivo endothelial function (Simons et al. 2000;
Lissin et al. 2004). Other, more novel, biomarkers of CVD
risk have been assessed in some studies included in the
present analysis, such as inflammatory factors, coagulatory
and fibrinolytic factors and markers of LDL oxidation
(Table 7; Jenkins et al. 2002; Steinberg et al. 2003;
Krebs et al. 2004; Hall et al. 2005; Teede et al.
2005). However, the number of these studies is very low
and no conclusions can be drawn from the data available
to date.
Health effects: climacteric symptoms
Consensus statement on climacteric symptoms: grade
A recommendation. There is currently limited evidence
that SPI, soyabean foods or red-clover extract are effective
in reducing menopausal symptoms. Soyabean-isoflavone
extracts may be effective in reducing hot flushes but
the effect is about half that observed with hormone-
replacement therapy and similar to that of other non-
hormonal pharmacological therapies.
Summary of data for climacteric symptoms. Epidemio-
logical evidence suggests that there is wide international
variability in the reporting of menopausal symptoms. In
particular, populations consuming soyabean as a staple
have a substantially reduced incidence compared with
Western populations (Lock, 1993). Three systematic
reviews on the effects of isoflavones and other herbal
remedies on menopausal symptoms have so far been pub-
lished (Huntley & Ernst, 2003, 2004; Krebs et al. 2004).
However, one review suggests some efficacy of soyabean
preparations (Huntley & Ernst, 2004), the second does not
support the hypothesis that isoflavones from a range of
sources improve menopausal symptoms (Krebs et al.
2004), while the third focuses on reviewing trials using
herbal remedies but only includes red clover as a source of
isoflavones (Huntley & Ernst, 2003). The effects of all
sources of phyto-oestrogens on menopausal symptoms
were therefore further evaluated using the criteria set out
earlier (Table 8). The main outcome measure in the studies
was the change in the number of hot flushes following
intervention, which was either qualitatively assessed (e.g.
using the Kupperman (1953) or Greene (1998) climacteric
scale) or quantified using diaries. Some of the studies also
quantified the effects of phyto-oestrogen sources on the
vaginal mucous, either subjectively by questioning the
subject’s perception of vaginal dryness or objectively
using a vaginal maturation index (as a measure of oestro-
genicity).
In total, twenty-four studies have examined the effect of
phyto-oestrogens on the incidence and severity of hot
flushes in peri- and post-menopausal women. Following
review only sixteen studies met the inclusion criteria
(Table 8). Four of these studies used SPI (Albertazzi et al.
1998; Kotsopoulos et al. 2000; Knight et al. 2001; St
Germain et al. 2001) in doses ranging from 28 to 85mg
aglycone equivalent (duration range 3–6 months), of which
three have observed no effects on the incidence of hot
flushes or vaginal dryness (Kotsopoulos et al. 2000; Knight
et al. 2001; St Germain et al. 2001). Only one of the four
studies has reported a decrease in hot flushes (Albertazzi
et al. 1998) and only one study has reported a beneficial
effect on vaginal dryness (Kotsopoulos et al. 2000). The
study that used a soyabean beverage has reported no
change in menopausal symptoms following intervention
(Van Patten et al. 2002). Three studies using red clover as
a source of isoflavones have indicated no effect either on
the incidence of hot flushes or vaginal epithelial cell
maturation (Baber et al. 1999; Knight et al. 1999; van
de Weijer & Barentsen, 2002). Seven studies have been
performed using isolated isoflavones at doses ranging from
32 to 72mg aglycones equivalents/d (Scambia et al. 2000;
Upmalis et al. 2000; Faure et al. 2002; Han et al. 2002;
Nikander et al. 2003; Penotti et al. 2003; Petri Nahas et al.
2004) and one using purified genistein (Crisafulli et al.
2004). Six of the studies have observed a significant
reduction in the occurrence of hot flushes (Scambia et al.
2000; Upmalis et al. 2000; Faure et al. 2002; Han et al.
2002; Crisafulli et al. 2004; Petri Nahas et al. 2004), but
Table 5. An overview of the effects of different soyabean products
on lipoprotein status and blood pressure in post-menopausal
women*
(The values represent the relative no. of trials showing an effect)
Soyabean product Lipoprotein status Blood pressure
Soya foods 3/3 0/1
Soyabean protein 9/13 2/3
Isoflavone extracts 2/12 0/5
*Trials reviewed: Atkinson et al. (2004a); Blum et al. (2003a,b); Campbell
et al. (2004); Cuevas et al. (2003); Desroches et al. (2004); Dewell et al.
(2002); Gardner et al. (2001); Han et al. (2002); Hodgson et al. (1998,
1999a,b); Howes et al. (2000); Lichtenstein et al. (2002); Lissin et al. (2004);
Mackey et al. (2000); Nestel et al. (1997, 1999); Nikander et al. (2003);
Puska et al. (2002); Simons et al. (2000); Squadrito et al. (2002, 2003);
Steinberg et al. (2003); Teede et al. (2001, 2003, 2005); Vigna et al. (2000);
Wangen et al. (2001); Washburn et al. (1999).
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only two of the studies have observed a difference in the
occurrence of other climacteric symptoms (Han et al.
2002; Petri Nahas et al. 2004). No change in vaginal
dryness has been observed following intervention in any of
the studies.
Health effects: breast cancer
Consensus statement on breast cancer: grade C recom-
mendation. On the basis of the available evidence the
panel has concluded that there is some epidemiological
evidence of an association between lifelong soyabean
intake and reduced risk of breast cancer in premenopausal
and post-menopausal women. Although to date three double-
blind RCT have been conducted, using mammographic
density as a marker of breast cancer risk, none of these
studies has examined effects in only post-menopausal
women. Further studies are required to address the poten-
tial effect of soyabean on breast cancer and to address the
current concerns of the potential risk–benefit profile of
soyabean isoflavones for breast-cancer survivors.
Summary of data on breast cancer. Several observa-
tional epidemiological studies have examined the relation-
ship between soyabean and breast cancer, relying on
varying measures of soyabean intake, ranging from
detailed analyses to crude estimates of the consumption of
tofu. Eight case–control studies have examined the asso-
ciation between soyabean intake and breast cancer risk in
Asian women in Singapore (Lee et al. 1991), Japan (Hirose
et al. 1995; Yamamoto et al. 2003) and China (Yuan et al.
1995; Shu et al. 2001; Dai et al. 2002), and in Asian-
Americans (Wu et al. 1996, 2002). Results from all these
studies consistently suggest an inverse association for both
premenopausal and post-menopausal breast cancer. In a
meta-analysis (A Wolk, unpublished results) of these
studies a significant 33% decreased risk of developing
breast cancer has been observed for post-menopausal
women (summary odds ratio 0.67 (95% CI 0.48, 0.93))
when comparing the highest consumption with the lowest
consumption in the respective study populations.
Fewer epidemiological studies have been conducted in
Caucasian women, given their limited exposure to soya-
bean-based products. In one case–control study of pre-
menopausal women from Germany (Linseisen et al. 2004)
and one prospective study of post-menopausal women
from The Netherlands (den Tonkelaar et al. 2001) sum-
mary estimates of risk are odds ratios of 0.61 (95% CI,
0.43, 0.86) and 0.83 (95% CI, 0.45, 1.50) respectively. A
recent Italian study has reported no association between
isoflavones and breast cancer risk in premenopausal or
post-menopausal women (Bosetti et al. 2005). The sum-
mary risk estimate indicates no association for post-
menopausal women (summary odds ratio 0.96 (95% CI
0.89, 1.04) based on the Dutch (den Tonkelaar et al. 2001)
and Italian (Bosetti et al. 2005) studies). The summary risk
estimate from the meta-analysis of two prospective studies
of total breast cancer (premenopausal and post-menopausal
women combined) among women from UK (Grace et al.
2004) and The Netherlands (Keinan-Boker et al. 2004) as
well as a case–control study from Australia (Ingram et al.
1997) is an odds ratio of 0.96 (95% CI, 0.71, 1.29).
To date two studies, one based in China (Shu et al.
2001) and the other in the USA (Wu et al. 2002), have
assessed the impact of adolescent dietary exposure in
Asian women on breast cancer risk. Both studies have
found a strong significant inverse association between
dietary soyabean and post-menopausal breast cancer risk,
with odds ratios of 0.49 (95% CI 0.33, 0.74) and 0.41
(P = 0.007 for trend).
Two prospective nested case–control studies of pre-
diagnostic urine in Caucasian women have shown con-
flicting results; a non-significant inverse association
between excreted genistein and breast cancer in Dutch
women (den Tonkelaar et al. 2001), and a positive asso-
ciation between excreted equol and breast cancer risk
(odds ratio 1.34 (95% CI 1.06, 1.70)) in English women
(Grace et al. 2004). Case–control studies analysing urine
collected after breast-cancer diagnosis have shown sig-
nificant inverse associations; one for the metabolite equol
(Ingram et al. 1997) and the other (in Asian women) in
relation to total isoflavone excretion (Dai et al. 2002; odds
ratios 0.27 (95% CI 0.1, 0.69) and 0.46 (95% CI 0.22, 0.95)
respectively).
Two cross-sectional studies (Maskarinec & Meng, 2001;
Jakes et al. 2002) have looked specifically at soyabean
intake and its association with breast tissue density.
Maskarinec & Meng (2001) have reported a higher density
with higher soyabean intake and a non-significant reduc-
tion in dense area, while Jakes et al. (2002) have shown
that higher soyabean intake is associated with lower risk
mammographic patterns (odds ratio 0.44 (95% CI 0.18,
0.96).
To date three double-blind RCT have been conducted,
two in premenopausal women (Maskarinec et al. 2003,
2004) and one with combined menopausal status (Atkinson
et al. 2004b). No significant differences in mammographic
characteristics that could be attributed to the soyabean
intervention were observed. However, it is possible that the
association between soyabean intake and breast density is
different in post-menopausal women, among those women
with a strong family history of the disease or in women
with polymorphisms in genes that encode oestrogen-
metabolising enzymes.
Health effects: colon cancer
Consensus statement on colon cancer: grade C recom-
mendation. The inconsistent results obtained by epi-
demiological studies provide no general support for the
hypothesis that frequent ingestion of soyabean reduces the
risk of colo-rectal cancer.
Summary of the data on colon cancer. Although the
incidence of colo-rectal cancer is markedly lower in many
Asian countries compared with Western populations, there
is limited support from epidemiological studies for a
potential protective role for soyabean and its isoflavones.
Numerous epidemiological studies, predominantly using a
case–control design, have examined the relationship
between intake of different soyabean foods and colo-rectal
cancer risk, but the data are contradictory (Haenszel et al.
1973; Watanabe et al. 1984; Tajima & Tominaga, 1985;
Hirayama, 1990; Hu et al. 1991; Hoshiyama et al. 1993;
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Le Marchand et al. 1997; Nishi et al. 1997; Seow et al.
2002).
In relation to colonic adenoma development two studies
have examined the effect of the consumption of soyabean
food on polyp growth (Kono et al. 1993; Witte et al.
1996). Although the findings from both studies are sug-
gestive of an inverse relationship between the intake of
miso soup (Kono et al. 1993) or tofu (Witte et al. 1996)
and the development of colo-rectal adenomas, the rela-
tionship was not found to be significant.
Health effects: cognitive function
Consensus statement on cognitive function: grade B
recommendation. As there are few available studies, it is
not possible to draw a conclusion on the effect of soyabean
products or isoflavones on cognitive function in post-
menopausal women.
Summary of the data on cognitive function. To date,
three studies (Kritz-Silverstein et al. 2003; Howes et al.
2004; Kreijkamp-Kaspers et al. 2004) have examined the
potential effects of phyto-oestrogens on cognitive function
in post-menopausal women (Table 9). The study duration
ranged from 6 to 12 months and the dose of isoflavones fed
daily ranged from 32 to 69mg aglycone equivalents. The
study with red clover (Kreijkamp-Kaspers et al. 2004) and
the study with SPI (Howes et al. 2004) do not show any
improvement in a range of cognitive tests such as verbal
memory, digit span (a measure of short-term memory) and
verbal fluency. The findings of the study performed with
soyabean isoflavone extracts suggest an improvement in
the category fluency (Kritz-Silverstein et al. 2003).
Health effects: diabetes
Consensus statement on the effect on diabetes: grade C
recommendation. There are limited studies that have
specifically focused on diabetic women, but the available
evidence suggests that there may be an effect of soyabean
on diabetes. However, more studies of longer duration are
needed to confirm this finding and to determine what active
components may be causing the changes.
Summary of data on diabetes. The prevalence of dia-
betes is reaching epidemic proportions and is increasing in
parallel with obesity. Cardiovascular mortality is up to five
times higher in women with diabetes compared with those
without diabetes, and the cardiovascular mortality rate is
increasing in diabetic women (Hu et al. 2001; Collins et al.
2003; Bibbins-Domingo et al. 2004). Women who develop
diabetes lose their cardiovascular protection from oestro-
gen, and post-menopausal oestrogen loss may contribute to
a high risk of accelerated CVD.
Ten studies have examined the effect of phyto-oestro-
gens on post-menopausal diabetes. Of these studies only
four (Hermansen et al. 2001; Jayagopal et al. 2002; Howes
et al. 2003; Li et al. 2005) met the inclusion criteria of
being focused on glycaemic control, but each study used
different variables and they are therefore difficult to
compare (Table 10). In addition, two studies used a mixed
population of men and women (Hermansen et al. 2001;
Li et al. 2005), whilst only two studies have focused on
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post-menopausal women alone (Jayagopal et al. 2002;
Howes et al. 2003), and these latter two studies used
markedly different isoflavone preparations. Hermansen
et al. (2001), using 50 g soyabean protein plus 160mg
isoflavone, have shown no change in glycaemic indices,
whilst Howes et al. (2003) have shown no change in over-
all glycaemic control using 50mg red-clover isoflavone
alone. Conversely, Jayagopal et al. (2002), using 30 g
soyabean protein plus 132mg isoflavone, have shown a
reduction in fasting insulin, glycosylated Hb and insulin
resistance. Li et al. (2005), using a soyabean-based meal
replacement, have shown a reduction in plasma glucose
and glycosylated Hb at 3 and 6 months, an effect that is
lost at 12 months. These studies suggest that a combination
of soyabean protein and isoflavones could have a positive
effect on diabetes control, although isoflavones alone may
not be effective and not all studies are positive. It is un-
clear which component(s) is active, and indeed it may be the
soluble fibre alone that is beneficial (Chandalia et al. 2000).
Summary and conclusions
The panel has concluded that because of the limited num-
ber of appropriately-designed studies and differences in
methodological approaches there is no conclusive evidence
on the different health aspects. However, the revision and
weighing of the available evidence has led the panel to
provide the following conclusions and recommendations,
each one with its associated grading:
1. there is a suggestion but no conclusive evidence that
isoflavones from the sources studied so far have a
beneficial effect on bone health: grade A;
2. the consumption of whole-soyabean foods and SPI has
beneficial effects on lipid markers of cardiovascular
risk in healthy post-menopausal women. The con-
sumption of isolated isoflavones does not affect blood
lipid levels or blood pressure, although it may improve
endothelial function: grade A;
3. for menopausal symptoms, there is currently limited
evidence that SPI, soyabean foods or red-clover
extract are effective but soyabean-isoflavone extracts
may be effective in reducing hot flushes: grade A;
4. there is some epidemiological evidence of an associa-
tion between lifelong soyabean intake and reduced risk
of breast cancer in premenopausal and post-menopau-
sal women. Although to date three double-blind RCT
have been conducted, using mammographic density as
a marker of breast cancer risk, none of these studies
has examined effects in only post-menopausal women:
grade C;
5. based on available evidence the consumption of
soyabean does not lead to reduced risk of colo-rectal
cancer: grade C;
6. based on available evidence soyabean products or
isoflavones do not have an effect on cognitive function
in post-menopausal women: grade B;
7. based on available evidence soyabean consumption
may reduce the risk of diabetes: grade C.
In conclusion, the use of soyabean products and soyabean
isoflavones may be beneficial in post-menopausal women
for bone, cardiovascular risk and hot flushes. However, the
benefits are subtle and do not appear in all individuals.
There are too few RCT studies to reach conclusions on
the effects of isoflavones on breast cancer, colon cancer,
diabetes or cognitive function.
Recommendations for research
Understanding the bioavailability of isoflavones in a given
foodstuff will be important in the interpretation of the
results of studies of clinical effects. Most importantly, it is
essential to measure accurately the amount and form of
isoflavones at the point of consumption during the
study, and to check this information at regular intervals.
Together, factors such as glycoside v. aglycone, food
source, the ‘equol-producer’ state of the volunteers and the
influence of other foods eaten during the study can deter-
mine whether a significant biological or clinical effect is
observed, or not.
Adequately-powered human intervention studies that can
definitely establish the benefits of either encapsulated iso-
flavones or isoflavone-fortified foods on clinical outcomes
such as the incidence of heart disease and bone fractures
are needed.
Appropriately-designed studies are required to examine
the effects of soyabean and soyabean isoflavones on breast
cancer, diabetes, colo-rectal cancer and cognitive function.
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